Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease

Mechanisms of Ageing and Development

Volumn 116, Issue 2-3, 2000, Pages 193-218

  Müller, Werner E G ^a   Laplanche, Jean Louis ^b   Ushijima, Hiroshi ^c   Schröder, Heinz C ^a  

^a Inst fur Physiologische Chemie   (Germany)

^b Serv de Biochim et Biol Molec   (France)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

14 3 3 protein; Apoptosis; Cerebrospinal fluid; Creutzfeldt Jakob disease; Flupirtine; Memantine; Neurotoxicity; NMDA receptor; Oxidative stress; Prion protein

Indexed keywords

FLUPIRTINE; MEMANTINE; PRION PROTEIN;

APOPTOSIS; CELL DEATH; CELL PROTECTION; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; DRUG EFFECT; HISTOPATHOLOGY; HUMAN; NEUROTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FOLDING; SCRAPIE; TARGET CELL;

ANIMAL; CELL DEATH; CREUTZFELDT-JAKOB SYNDROME; HUMAN; NEURONS; PRION DISEASES; PRPSC PROTEINS; SUPPORT, NON-U.S. GOV'T;

EID: 0342409474     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-6374(00)00112-3     Document Type: Conference Paper

References (167)

1. Adjou K.T., Demaimay R., Lasmezas C., Deslys J.P., Seman M., Dormont D. MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob. Agents Chemother. 39:1995;2810-2812.
2. Adjou K.T., Demaimay R., Deslys J.P., Lasmezas C.I., Beringue V., Demart S., Lamoury F., Seman M., Dormont D. MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. J. Gen. Virol. 80:1999;1079-1085.
3. Aitken A., Collinge D.B., v. Heusden B.P.H., Isobe T., Roseboom P.H., Rosenfeld G., Soll J. 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem. Sci. 17:1992;498-501.
4. Aitken A., Jones D., Soneji Y., Howell S. 14-3-3 proteins: biological function and domain structure. Biochem. Soc. Trans. 23:1995;605-611.
5. Baxter, H.C., Forster, J.L., Steinacker, P., Otto, M., Wiltfang, J., Poser, S., Aitken, A., 1999. Development of a 14-3-3 isoform specific ELISA. Abstract Book, International Symposium 'Characterization and Diagnosis of Prion Diseases in Animals and Man', September 23rd-25th, 1999, Tübingen, Germany, p. 103.
6. Beaudry P., Cohen P., Brandel J.P., Delasnerie-Laupretre N., Richard S., Launay J.M., Laplanche J.L. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 10:1999;40-46.
7. Bebenburg W.v., Engel J., Sheldrik W.S. Synthese und Molekülstruktur des konstitutionell neuartigen Analgetikums Flupirtin. Chemiker-Ztg. 105:1981;217-219.
8. Bendheim P.E., Brown H.R., Rudelli R.D. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology. 42:1992;149-156.
9. Blisard K.S., Davis L.E., Harrington M.G., Lovell J.K., Kornfeld M., Berger M.L. Pre-mortem diagnosis of Creutzfeldt-Jakob disease by detection of abnormal cerebrospinal fluid proteins. J. Neurol. Sci. 99:1990;75-81.
10. Block F., Pergande G., Schwarz M. Flupirtine protects against ischemic retinal dysfunction in rats. Neuroreport. 5:1994;2630-2632.
11. Block F., Pergande G., Schwarz M. Flupirtine reduces functional and morphological consequences induced by global ischemia in rats. Eur. J. Neurosci. Suppl. 8:1995;24.
12. Block F., Pergande G., Schwarz M. Flupirtine reduces functional deficits and neuronal damage after global ischemia in rats. Brain Res. 754:1997;279-284.
13. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166:1989;591-592.
14. Brandel J.P. Clinical aspects of human spongiform encephalopathies, with the exception of iatrogenic forms. Biomed. Pharmacother. 53:1999;14-18.
15. Brandel J.P., Beaudry P., Delasnerie-Laupretre N., Laplanche J.L. Creutzfeldt-Jakob disease: diagnostic value of protein 14-3-3 and neuronal specific enolase assay in cerebrospinal fluid. Rev. Neurol. Paris. 155:1999;148-151.
16. Brandel, J.P., Beaudry, P., Bottos, C., Peoc'h, K., Lauprêtre, N., Laplanche, J.L., 1999b. 14-3-3 protein CSF detection in human growth hormone treated CJD patients. Abstract Book, International Symposium 'Characterization and Diagnosis of Prion Diseases in Animals and Man', September 23rd-25th, 1999, Tübingen, Germany, p. 101.
17. Bredesen D.E. Neuronal apoptosis: genetic and biochemical modulation. Tomei L.D., Cope F.O. Apoptosis II: The Molecular Basis of Apoptosis in Disease. 1994;397-421 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
18. Brown D.R. Prion protein peptide neurotoxicity can be mediated by astrocytes. J. Neurochem. 73:1999;1105-1113.
19. Brown D.R., Kretzschmar H.A. Microglia and prion disease: a review. Histol. Histopathol. 12:1997;883-892.
20. Brown D.R., Mohn C.M. Astrocytic glutamate uptake and prion protein expression. Glia. 25:1999;282-292.
21. Brown D.R., Herms J., Kretzschmar H.A. Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment. Neuroreport. 5:1994;2057-2060.
22. Brown D.R., Schmidt S., Kretzschmar H.A. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature. 380:1996;345-347.
23. Brown D.R., Herms J.W., Schmidt B., Kretzschmar H.A. PrP and β-amyloid fragments activate different neurotoxic mechanisms in cultured mouse cells. Eur. J. Neurosci. 9:1997;1162-1169.
24. Bruce M.E., Will R.G., Ironside J.W., McConnell I., Drummond D., Suttie A., McCardle L., Chree A., Hope J., Birkett C., Cousens S., Fraser H., Bostock C.J. Transmission to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 389:1997;498-501.
25. Cashman N.R., Loertscher R., Nalbantoglu J., Shaw I., Kascsak R.J., Bolton D.C., Bendheim P.E. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell. 61:1990;185-192.
26. Caspi S., Halimi M., Yanai A., Sasson S.B., Taraboulos A., Gabizon R. The anti-prion activity of Congo red. Putative mechanism. J. Biol. Chem. 273:1998;3484-3489.
27. Caughey B., Race R.E. Potent inhibition of scrapie-associated PrP accumulation by congo red. J. Neurochem. 59:1992;768-771.
28. Caughey B., Raymond G.J. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67:1993;643-650.
29. Caughey B.W., Dong A., Bhat K.S., Ernst D., Hayes S.F., Caughey W.S. Secondary structural analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry. 30:1991;7672-7680.
30. Chakraborti T., Das S., Mondal M., Roychoudhury S., Chakraborti S. Oxidant, mitochondria and calcium: an overview. Cell Signal. 11:1999;77-85.
31. Collinge J., Whittington M.A., Sidle K.C., Smith C.J., Palmer M.S., Clarke A.R., Jefferys J.G. Prion protein is necessary for normal synaptic function. Nature. 370:1994;295-297.
32. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev. 21:1997;455-468.
33. Demaimay R., Race R., Chesebro B. Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons. J. Virol. 73:1999;3511-3513.
34. De Silva R., Findlay C., Awad I., Harries-Jones R., Knight R., Will R. Creutzfeldt-Jakob disease in the elderly. Postgrad. Med. J. 73:1997;557-559.
35. Diomede L., Sozzani S., Luini W., Algeri M., De Gioia L., Chiesa R., Lievens P.M., Bugiani O., Forloni G., Tagliavini F., Salmona M. Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes. Biochem. J. 320:1996;563-570.
36. Diringer H., Ehlers B. Chemoprophylaxis of scrapie in mice. J. Gen. Virol. 72:1991;457-460.
37. Fairbairn D.W., Carnahan K.G., Thwaits R.N., Grigsby R.V., Holyoak G.R., O'Neill K.L. Detection of apoptosis induced DNA cleavage in scrapie-infected sheep brain. FEMS Microbiol. Lett. 115:1994;341-346.
38. Fanger G.R., Widmann C., Porter A.C., Sather S., Johnson G.L., Vaillancourt R.R. 14-3-3 proteins interact with specific MEK kinases. J. Biol. Chem. 273:1998;3476-3483.
39. Fantl W.J., Muslin A.J., Kikuchi A., Martin J.A., MacNicol A.M., Gross R.W., Williams L.T. Activation of Raf-1 by 14-3-3 proteins. Nature. 371:1994;612-614.
40. Florio T., Grimaldi M., Scorziello A., Salmona M., Bugiani O., Tagliavini F., Forloni G., Schettini G. Intracellular calcium rise through L-type calcium channels, as molecular mechanism for prion protein fragment 106-126-induced astroglial proliferation. Biochem. Biophys. Res. Commun. 228:1996;397-405.
41. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O., Tagliavini F. Neurotoxicity of a prion protein fragment. Nature. 362:1993;543-546.
42. Fox N., Harvey R.J., Rossor M.N. Protein folding, nucleation phenomena and delayed neurodegeneration in Alzheimer's disease. Rev. Neurosci. 7:1996;21-28.
43. Friedel H.A., Fitton A. Flupirtine: a review of its pharmacological properties, and therapeutic efficacy in pain patients. Drug. 45:1993;548-569.
44. Gambetti P., Parchi P., Petersen R.B., Chen S.G., Lugaresi E. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. Brain Pathol. 5:1995;43-51.
45. Gasset M., Baldwin M.A., Lloyd D.H., Gabriel J.M., Holtzman D.M., Cohen F., Fletterick R., Prusiner S.B. Peptide α-helical regions of the prion protein when synthesized as peptides form amyloid. Proc. Natl. Acad. Sci. USA. 89:1992;10940-10944.
46. Giese A., Groschup M.H., Hess B., Kretzschmar H.A. Neuronal cell death in scrapie-infected mice is due to apoptosis. Brain Pathol. 5:1995;213-221.
47. Harrington M.G., Merril C.R., Asher D.M., Gajdusek D.C. Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N. Engl. J. Med. 315:1986;279-283.
48. Hesselink M.B., De Boer B.G., Breimer D.D., Danysz W. Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and Memantine: a quantitative microdialysis study. Pharm. Res. 16:1999;637-642.
49. Hockenbery D.M., Oltvai Z.N., Yin X.M., Milliman C.L., Korsmeyer S.J. Bcl-functions in an antioxidant pathway to prevent apoptosis. Cell. 75:1993;241-251.
50. Hope J., Shearman M.S., Baxter H.C., Chong A., Kelly S.M., Price N.C. Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, Aβ 25-35. Neurodegeneration. 5:1996;1-11.
51. Hsich G., Kenney K., Gibbs C.J., Lee K.H., Harrington M.G. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N. Engl. J. Med. 335:1996;924-930.
52. Huettner J.E., Bean B.P. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc. Natl. Acad. Sci. USA. 85:1988;1307-1311.
53. Itano Y., Nomura Y. 1-methyl-4-phenyl-pyridinium ion (MPP+) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms. Brain Res. 704:1995;240-245.
54. Jacobson M.D. Reactive oxygen species and programmed cell death. Trends Biochem. Sci. 21:1996;83-86.
55. Jacobson M.D., Raff M.C. Programmed cell death and Bcl-2 protection in very low oxygen. Nature. 374:1995;814-816.
56. Jesionek-Kupnicka D., Buczynski J., Kordek R., Sobow T., Kloszewska I., Papierz W., Liberski P.P. Programmed cell death (apoptosis) in Alzheimer's disease and Creutzfeldt-Jakob disease. Folia Neuropathol. 35:1997;233-235.
57. Jimi T., Wakayama Y., Shibuya S., Nakata H., Tomaru T., Takahashi Y., Kosaka K., Asano T., Kato K. High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin. Chim. Acta. 211:1992;37-46.
58. Kannenberg K., Groschup M.H., Sigel E. Cellular prion protein and GABA receptors: no physical association? Neuroreport. 7:1995;77-80.
59. Kellings K., Meyer N., Mirenda C., Prusiner S.B., Riesner D. Further analysis of nucleic acids in purified scrapie prion preparations by improved return refocusing gel electrophoresis. J. Gen. Virol. 73:1992;1025-1029.
60. Knight R. Creutzfeldt-Jakob disease: clinical features, epidemiology and tests. Electrophoresis. 19:1998;1306-1310.
61. Kornhuber J., Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist Memantine in man. Neurosci. Lett. 195:1995;137-139.
62. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166:1989;589-590.
63. Kornhuber J., Bormann J., Hübers M., Rusche K., Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol. 206:1991;297-300.
64. Korsmeyer S.J., Yin X.M., Oltvai Z.N., Veis-Novack D.J., Linette G.P. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim. Biophys. Acta. 1271:1995;63-66.
65. Kretzschmar H.A. Human prion diseases (spongiform encephalopathies). Arch. Virol. Suppl. 7:1993;261-293.
66. Kretzschmar H.A., Ironside J.W., DeArmond S.J., Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch. Neurol. 53:1996;913-920.
67. Kropp S., Zerr I., Schulz-Schaeffer W.J., Riedemann C., Bodemer M., Laske C., Kretzschmar H.A., Poser S. Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 261:1999;124-126.
68. Kurschner C., Morgan J.I. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system. Brain Res. Mol. Brain Res. 30:1995;165-168.
69. Labalette M., Queyrel V., Masy E., Noel C., Pruvot F.R., Dessaint J.P. Implication of cyclosporine in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients. Transplantation. 59:1995;1714-1723.
70. Lange K.W., Riederer P. The neurotoxicity of glutamate. Kempski O. Glutamate-Transmitter and Toxin. 1993;30-43 Zuckschwerdt Verlag, München.
71. Lawrence M.S., Ho D.Y., Sun G.H., Steinberg G.K., Sapolsky R.M. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. J. Neurosci. 16:1996;486-496.
72. Lee K.H., Harrington M.G. Premortem diagnosis of Creutzfeldt-Jakob disease by cerebrospinal fluid analysis. Lancet. 348:1996;887.
73. Lee K.H., Harrington M.G. The assay development of a molecular marker for transmissible spongiform encephalopathies. Electrophoresis. 18:1997;502-506.
74. Leuck, J., Peoc'h, K., Laplanche, J.-L., Grabar, E., Müller, W.E.G., Schröder, H.C., 2000. A novel binding assay for detection of 14-3-3 protein in cerebrospinal fluid from Creutzfeldt-Jakob patients. Cell. Mol. Biol. (in press).
75. Lin M.C., Mirzabekov T., Kagan B.L. Channel formation by a neurotoxic prion protein fragment. J. Biol. Chem. 272:1997;44-47.
76. Lipton S.A. Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology. 42:1992;1403-1405.
77. Lipton S.A., Sucher N.J., Kaiser P.K., Dreyer E.B. Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron. 7:1991;111-118.
78. Lo A.C., Houenou L.J., Oppenheim R.W. Apoptosis in the nervous system: morphological features, methods, pathology, and prevention. Arch. Histol. Cytol. 58:1995;139-149.
79. Lorenz B., Schlüter T., Bohnensack R., Pergande G., Müller W.E.G. Effect of Flupirtine on cell death of human umbilical vein endothelial cells induced by reactive oxygen species. Biochem. Pharmacol. 56:1998;1615-1624.
80. Lucassen P.J., Williams A., Chung W.C., Fraser H. Detection of apoptosis in murine scrapie. Neurosci. Lett. 198:1995;185-188.
81. Macario M.E., Moura-Neto V., Vaisman M., Araujo H.M., Buescu A., Cordeiro J.G., Chagas C. Abnormal proteins in the cerebrospinal fluid of a patient with Creutzfeldt-Jakob disease following administration of human pituitary growth hormone. Braz. J. Med. Biol. Res. 25:1992;1127-1130.
82. Maier-Lenz H., Thieme G. Kumulationskinetik von Flupirtin (D 9998) bei oraler Applikation. 1983;Forschungsbericht Asta-Medica, Frankfurt.
83. McKenzie D., Kaczkowski J., Marsh R., Aiken J. Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection. J. Virol. 68:1994;7534-7536.
84. McMahon F.G., Arndt W.F., Newton J.J., Montgomery P.A., Perhach J.L. Clinical experience with Flupirtine in the U.S. Postgrad. Med. J. 63:1987;81-85.
85. Medori R., Tritschler H.J., LeBlanc A., Villare F., Manetto V., Chen H.Y., Xue R., Leal S., Montagna P., Cortelli P., et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N. Engl. J. Med. 326:1992;444-449.
86. Meister A., Anderson M.E. Glutathione. Annu. Rev. Biochem. 52:1983;711-760.
87. Michaelidis T.M., Sendtner M., Cooper J.D., Airaksinen M.S., Holtmann B., Meyer M., Thoenen H. Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron. 17:1996;75-89.
88. Moore B.W., Perez V.J. Specific acidic proteins of the nervouse system. Carlson F.D. Physiological and Biochemical Aspects of Nervous Integration. 1967;343-359 Prentice-Hall, Englewood Cliffs, NJ.
89. Müller, W.E.G., Schröder, H.C., Anwendung der 14-3-3 Proteine als sensitive Biomarker für Pollution u. a. mit polychlorierten Biphenylen (PCBs) und (Xeno) Östrogenen sowie Verfahren zur schnellen Bestimmung der 14-3-3 Proteine. Europäische Patentamt (PCT/EP 99/01545), 1999.
90. Müller W.E.G., Schröder H.C., Ushijima H., Dapper J., Bormann J. Gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by Memantine. Eur. J. Pharmacol. 226:1992;209-214.
91. Sc)-induced toxicity in rat cortical cell culture. Eur. J. Pharmacol. 246:1993;261-267.
92. Müller W.E., Pergande G., Ushijima H., Schleger C., Kelve M., Perovic S. Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention. Prog. Mol. Subcell. Biol. 16:1996;44-57.
93. Müller W.E.G., Dobmeyer J.M., Dobmeyer T.S., Pergande G., Perovic S., Leuck J., Rossol R. Flupirtine protects both neuronal cells and lymphocytes against induced apoptotic death in vitro: Implications for treatment of AIDS patients. Death Differ. 4:1997;51-58.
94. Müller W.E.G., Romero F.J., Perovic S., Pergande G., Pialoglou P. Protection of Flupirtine on β-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. J. Neurochem. 68:1997;2371-2377.
95. Muslin A.J., Tanner J.W., Allen P.M., Shaw A.S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 84:1996;889-897.
96. Nguyen J., Baldwin M.A., Cohen F.E., Prusiner S.B. Prion protein peptides induce α-helix to β-sheet conformational transitions. Biochemistry. 34:1995;4186-4192.
97. Obermeier K., Niebich G., Thiemer K. Untersuchungen zur Pharmakokinetik und Biotransformation des Analgetikums Flupirtin bei Ratte und Hund. Arzneim. Forsch./Drug. Res. 35:1985;60-67.
98. Olney J.W. Excitatory transmitter neurotoxicity: an overview. Kempski O. Glutamate-Transmitter and Toxin. 1993;3-11 Zuckschwerdt Verlag, München.
99. Osborne N.N., Pergande G., Block F., Schwarz M. Immunohistochemical evidence for Flupirtine acting as an antagonist on the N-methyl-D-aspartate (NMDA) and homocysteic acid-induced release of GABA in the rabbit retina. Brain Res. 667:1994;291-294.
100. Osborne N.N., Schwarz M., Pergande G. Protection of rabbit retina from ischemic injury by flupirtine. Invest. Ophthaomol. Vis. Sa. 37:1996;274-280.
101. Osborne N.N., Cazevieille C., Pergande G., Wood J.P. Induction of apoptosis in cultured human retinal pigment epithelial cells is counteracted by Flupirtine. Invest. Ophthalmol. Vis. Sci. 38:1997;1390-1400.
102. Osborne N.N., Cazevieille C., Wood J.P., Nash M.S., Pergande G., Block F., Kosinski C., Schwarz M. Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist. Gen. Pharmacol. 30:1998;255-263.
103. Otto M., Stein H., Szudra A., Zerr I., Bodemer M., Gefeller O., Poser S., Kretzschmar H.A., Mader M., Weber T. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J. Neurol. 244:1997;566-570.
104. Pammer J., Weninger W., Tschachler E. Human keratinocytes express cellular prion-related protein in vitro and during inflammatory skin diseases. Am. J. Pathol. 153:1998;1353-1358.
105. Pan K.M., Baldwin M., Nguyen J., Gasset M., Serban A., Groth D., Mehlhorn I., Huang Z., Fletterick R.J., Cohen F.E., et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA. 90:1993;10962-10966.
106. Parchi P., Petersen R.B., Chen S.G., Autilio-Gambetti L., Capellari S., Monari L., Cortelli P., Montagna P., Lugaresi E., Gambetti P. Molecular pathology of fatal familial insomnia. Brain Pathol. 8:1998;539-548.
107. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 38:1999;735-767.
108. Pauly P.C., Harris D.A. Copper stimulates endocytosis of the prion protein. J. Biol. Chem. 273:1998;33107-33110.
109. Perez M., Wandosell F., Colaco C., Avila J. Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment. Biochem. J. 335:1998;369-374.
110. Perovic S., Schleger C., Pergande G., Iskric S., Ushijima H., Rytik P., Müller W.E.G. The triaminopyridine Flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur. J. Pharmacol. 288:1994;27-33.
111. Perovic S., Pergande G., Ushijima H., Kelve M., Forrest J., Müller W.E.G. Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration. 4:1995;369-374.
112. Perovic S., Pialoglou P., Schröder H.C., Pergande G., Müller W.E.G. Flupirtine increases the levels of glutathione and Bcl-2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect. Eur. J. Pharmacol. 317:1996;157-164.
113. Perovic S., Schröder H.C., Pergande G., Ushijima H., Müller W.E.G. Effect of Flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp. Neurol. 147:1997;518-524.
114. Perovic S., Böhm M., Meesters E., Meinhardt A., Pergande G., Müller W.E.G. Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases. Mech. Ageing Dev. 101:1998;1-19.
115. Piccardo P., Dlouhy S.R., Lievens P.M., Young K., Bird T.D., Nochlin D., Dickson D.W., Vinters H.V., Zimmerman T.R., Mackenzie I.R., Kish S.J., Ang L.C., De Carli C., Pocchiari M., Brown P., Gibbs C.J. Jr, Gajdusek D.C., Bugiani O., Ironside J., Tagliavini F., Ghetti B. Phenotypic variability of Gerstmann-Straussler-Scheinker disease is associated with prion protein heterogeneity. J. Neuropathol. Exp. Neurol. 57:1998;979-988.
116. Pocchiari M., Casaccia P., Ladogana A. Amphotericin B: a novel class of antiscrapie drugs. J. Infect. Dis. 160:1989;795-802.
117. Prusiner S.B. Biology and genetics of prion diseases. Annu. Rev. Microbiol. 48:1994;655-686.
118. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. USA. 95:1998;13363-13383.
119. Ratan R.P., Baraban J.M. Apoptotic death in an in vitro model of neuronal oxidative stress. Clin. Exp. Pharmacol. Physiol. 22:1995;309-310.
120. Rieger R., Lasmezas C.I., Weiss S. Role of the 37 kDa laminin receptor precursor in the life cycle of prions. Transfus. Clin. Biol. 6:1999;7-16.
121. Rosenmann H., Meiner Z., Kahana E., Halimi M., Lenetsky E., Abramsky O., Gabizon R. Detection of 14-3-3 protein in the CSF of genetic Creutzfeldt-Jakob disease. Neurology. 49:1997;593-595.
122. Ruffie A., Delasnerie-Laupretre N., Brandel J.P., Jaussent I., Dormont D., Laplanche J.L., Hauw J.J., Richardson S., Alperovitch A. Incidence of Creutzfeldt-Jakob disease in France, 1992-1995. Rev. Epidemiol. Sante Publique. 45:1997;448-453.
123. 2+ concentrations. Eur. J. Pharmacol. 294:1995;469-473.
124. Sagot Y., Dubois-Dauphin M., Tan S.A., de Bilbao F., Aebischer P., Martinou J.C., Kato A.C. Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. J. Neurosci. 15:1995;7727-7733.
125. Sasaki A., Hirato J., Nakazato Y. Immunohistochemical study of microglia in the Creutzfeldt-Jakob diseased brain. Acta Neuropathol. Berl. 86:1993;337-344.
126. Savio T., Levi G. Neurotoxicity of HIV coat protein gp120, NMDA receptors and protein kinase C: a study with cerebellar granule cell cultures. J. Neurosci. Res. 34:1993;265-272.
127. Scallet A.C., Ye X. Excitotoxic mechanisms of neurodegeneration in transmissible spongiform encephalopathies. Ann. N. Y. Acad. Sci. 825:1997;194-205.
128. Schatzl H.M., Laszlo L., Holtzman D.M., Tatzelt J., DeArmond S.J., Weiner R.I., Mobley W.C., Prusiner S.B. A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J. Virol. 71:1997;8821-8831.
129. Schendel S.L., Montal M., Reed J.C. Bcl-2 family proteins as ion-channels. Cell Death Differ. 5:1998;372-380.
130. Schröder H.C., Scheffer U., Forrest J.M.S., Sève A.-P., Rytik P.G., Müller W.E.G. Association of scrapie prion protein and prion protein-RNA stem-loop with nuclear carbohydrate-binding protein 35 and other RNA-binding proteins. Neurodegeneration. 3:1994;177-189.
131. Schröder, H.C., Müller, W.E.G., Forrest, J.M.S., 2000. Lectins as diagnostic tools and endogenous targets in AIDS and prion diseases. In: Caron, M., Sève, A.P. (Ed.), Lectins and Pathology. Harwood Academic, Publ., Amsterdam, The Netherlands, pp. 123-134.
132. Sc- and HIV-1 gp120 induced neuronal cell death. NeuroToxicology. 19:1998;683-688.
133. Schwarz M., Block F., Pergande G. NMDA-mediated muscle relaxant action of Flupirtine in rats. Neuro-Report. 5:1994;1981-1984.
134. 2-adrenergic mechanisms are involved in the depressant action of Flupirtine on spinal reflexes in rats. Eur. J. Pharmacol. 276:1995;247-255.
135. Seilhean D., Duyckaerts C., Hauw J.J. Fatal familial insomnia and prion diseases. Rev. Neurol. Paris. 151:1995;225-230.
136. C, in cultured cells. J. Biol. Chem. 270:1995;30221-30229.
137. Silei V., Fabrizi C., Venturini G., Salmona M., Bugiani O., Tagliavini F., Lauro G.M. Activation of microglial cells by PrP and β-amyloid fragments raises intracellular calcium through L-type voltage sensitive calcium channels. Brain Res. 818:1999;168-170.
138. Slater A.F., Nobel C.S., Orrenius S. The role of intracellular oxidants in apoptosis. Biochim. Biophys. Acta. 1271:1995;59-62.
139. Sticht H., Bayer P., Willbold D., Dames S., Hilbich C., Beyreuther K., Frank R.W., Rosch P. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur. J. Biochem. 233:1995;293-298.
140. Szelenyi I., Nickel B., Borbe H.O., Brune K. Mode of antinociceptive action of Flupirtine in the rat. Br. J. Pharmacol. 97:1989;835-842.
141. Tagliavini F., McArthur R.A., Canciani B., Giaccone G., Porro M., Bugiani M., Lievens P.M., Bugiani O., Peri E., Dall'Ara P., Rocchi M., Poli G., Forloni G., Bandiera T., Varasi M., Suarato A., Cassutti P., Cervini M.A., Lansen J., Salmona M., Post C. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science. 276:1997;1119-1122.
142. Takahashi H., Iwata T., Kitagawa Y., Takahashi R.H., Sato Y., Wakabayashi H., Takashima M., Kido H., Nagashima K., Kenney K., Gibbs C.J. Jr, Kurata T. Increased levels of ε and γ isoforms of 14-3-3 proteins incerebrospinal fluid in patients with Creutzfeldt-Jakob disease. Clin. Diagn. Lab. Immunol. 6:1999;983-985.
143. Taraboulos A., Serban D., Prusiner S.B. Scrapie prion proteins accumulate in the cytoplasm of persistently infected cultured cells. J. Cell Biol. 110:1990;2117-2132.
144. Tatzelt J., Voellmy R., Welch W.J. Abnormalities in stress proteins in prion diseases. Cell. Mol. Neurobiol. 18:1998;721-729.
145. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
146. Ushijima H., Ando S., Kunisada T., Schröder H.C., Klöcking H.P., Kijjoa A., Müller W.E.G. HIV-1 gp120 and NMDA induce protein kinase C translocation differentially in rat primary neuronal cultures. J. Acquir. Immune Defic. Syndr. 6:1993;339-343.
147. Ushijima H., Nishio O., Klöcking R., Perovic S., Müller W.E.G. Exposure to gp120 of HIV-1 induces an increased release of arachidonic acid in rat primary neuronal cell culture followed by NMDA receptor mediated neurotoxicity. Eur. J. Neurosci. 7:1995;1353-1359.
148. Sc- and HIV-1 gp120 induced neuronal cell death by sulfated colominic acid. J. NeuroVirol. 5:1999;289-299.
149. Wakayama Y., Shibuya S., Kawase J., Sagawa F., Hashizume Y. High neuron-specific enolase level of cerebrospinal fluid in the early stage of Creutzfeldt-Jakob disease. Klin. Wochenschr. 65:1987;798-801.
150. Wallace M. Creutzfeldt-Jakob disease: assessment and management. J. Gerontol. Nurs. 19:1993;15-22.
151. Weber T., Aguzzi A. The spectrum of transmissible spongiform encephalopathies. Intervirology. 40:1997;198-212.
152. Weber T., Otto M., Bodemer M., Zerr I. Diagnosis of Creutzfeldt-Jakob disease and related human spongiform encephalopathies. Biomed. Pharmacother. 51:1997;381-387.
153. Whatley S.A., Powell J.F., Politopoulou G., Campbell I.C., Brammer M.J., Percy N.S. Regulation of intracellular free calcium levels by the cellular prion protein. Neuroreport. 6:1995;2333-2337.
154. White A.R., Bush A.I., Beyreuther K., Masters C.L., Cappai R. Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione. J. Neurochem. 72:1999;2092-2098.
155. Wiedau-Pazos M., Trudell J.R., Altenbach C., Kane D.J., Hubbell W.L., Bredesen D.E. Expression of Bcl-2 inhibits cellular radical generation. Free Radic. Res. 24:1996;205-212.
156. Wiens M., Koziol C., Hassanein H.M.A., Batel R., Schröder H.C., Müller W.E.G. Induction of gene expression of the chaperones 14-3-3 and HSP70 by PCB118 (2,3′,4,4′,5-pentachlorobiphenyl) in the marine sponge Geodia cydonium: novel biomarkers for polychlorinated biphenyls. Mar. Ecol. Prog. Ser. 165:1998;247-257.
157. Will R.G., Zeidler M., Brown P., Harrington M., Lee K.H., Kenney K.L. Cerebrospinal-fluid test for new-variant Creutzfeldt-Jakob disease. Lancet. 348:1996;955.
158. Wiltfang J., Otto M., Baxter H.C., Bodemer M., Steinacker P., Bahn E., Zerr I., Kornhuber J., Kretzschmar H.A., Poser S., Ruther E., Aitken A. Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J. Neurochem. 73:1999;2485-2490.
159. Wyllie A.H., Kerr J.F.R., Currie A.R. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:1980;251-306.
160. Yaffe M.B., Rittinger K., Volinia S., Caron P.R., Aitken A., Leffers H., Gamblin S.J., Smerdon S.J., Cantley L.C. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell. 91:1997;961-971.
161. Younkin D.P., Tang C.M., Hardy M., Reddy U.R., Shi Q.Y., Pleasure S.J., Lee V.M.Y., Pleasure D. Inducible expression of neuronal glutamate receptor channels in the NT2 human cell line. Proc. Natl. Acad. Sci. USA. 90:1993;2174-2178.
162. Zerr I., Bodemer M., Racker S., Grosche S., Poser S., Kretzschmar H.A., Weber T. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet. 345:1995;1609-1610.
163. Zerr I., Bodemer M., Otto M., Poser S., Windl O., Kretzschmar H.A., Gefeller O., Weber T. Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet. 348:1996;846-849.
164. Zerr I., Bodemer M., Gefeller O., Otto M., Poser S., Wiltfang J., Windl O., Kretzschmar H.A., Weber T. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann. Neurol. 43:1998;32-40.
165. L. Cell. 87:1996;619-628.
166. Zhong L.T., Kane D.J., Bredesen D.E. BCL-2 blocks glutamate toxicity in neural cell lines. Brain Res. Mol. Brain Res. 19:1993;353-355.
167. Zimmer G., Balakirev M., Zwicker K., Hofmann M., Woodcock B.G., Pergande G. Effect of the triaminopyridine Flupirtine on calcium uptake, membrane potential and ATP synthesis in rat heart mitochondria. Br. J. Pharmacol. 123:1998;1154-1158.